Navigation Links
Egenix Licenses Harvard Anti-Cancer Platform
Date:1/31/2008

MILLBROOK, N.Y., Jan. 31 /PRNewswire/ -- Mr. Donald Fresne, Chairman and CEO of Egenix, Inc., announced today that the company has recently obtained from Harvard University a field-exclusive license under patent rights that cover certain technologies related to cancer therapy and prognostic testing. The licensed technologies, which were developed jointly by scientists in the Laboratory for Translational Research and the Department of Biological Chemistry and Molecular Pharmacology, each of Harvard Medical School, comprise small molecule inhibitors of translation initiation, a new paradigm in target- specific, non-cytotoxic anti-cancer therapy, and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anti-cancer therapy with this novel class of anti-cancer drugs. Specifically, the inhibitors of translation initiation licensed by Egenix from Harvard Medical School target the eIF4F and ternary complexes, the two critical regulators of messenger RNA translation into protein.

The company's management believes that small molecules for the inhibition of translation initiation are at the forefront of modern cancer therapeutics currently under development and that this cutting-edge platform has the potential to yield significant breakthroughs in the biomedical field for the treatment of cancer.

About Egenix, Inc.

Based in Millbrook, New York, Egenix, Inc. is a privately held biotechnology company responding to the demand for more effective cancer therapies.

Terms and conditions of the license agreement are not disclosed.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
2. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
3. Prometheus Licenses COLAL-PRED(R) From Alizyme
4. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
5. Syngenta Licenses Chromatin Gene Stacking Technology
6. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
7. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
8. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
9. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
10. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):